Our Leadership
Management Committee Executive Group
Shinichiro Hirose
Chair, IGBA
Director of International Affairs, Japan Generic Medicines Association (JGA)
Shinichiro Hirose is the director of international affairs at the Japan Generic Medicines Association (JGA), a member association of the IGBA. In this position, he is responsible for coordinating activities on international affairs and other expert committees of the association. He is a member of IGBA management committee, and other standing committees. He is also engaged in ICH project, taking a role as ICH coordinator for IGBA. Before joining JGA, he worked for pharmaceutical industry over 30 years, and has experiences in research, business development, and marketing for international markets. He holds the Ph.D. degree in pharmaceutical sciences from the university of Tokyo, Japan.
Jim Keon
Vice-Chair, IGBA
President, Canadian Generic Pharmaceutical Association
President, Biosimilars Canada
Jim Keon is President of the Canadian Generic Pharmaceutical Association (CGPA), and President of Biosimilars Canada organizations representing Canada’s generic and biosimilar pharmaceutical sectors. Jim graduated with an M.A. in Economics from Queen’s University and has more than 30 years experience in the pharmaceutical sector. Jim has served as President of the CGPA since 1998 and was named the founding President of Biosimilars Canada in January 2015. Prior to joining CGPA in 1994 he held senior positions in the federal government and was directly involved in international trade negotiations for NAFTA and the WTO, as well as Canada’s inter-provincial trade negotiations. Jim is a past Chair and is currently Vice Chair (2025) of the Management Committee of the International Generic and Biosimilars Medicines Association (IGBA). The IGBA is committed to promoting the interests of generic and biosimilars medicines around the world.
Adrian van den Hoven
Immediate Past Chair IGBA
Director General, Medicines for Europe
Adrian van den Hoven has been director general of Medicines for Europe since September 2013.
In his role he focuses on stimulating competition in off-patent medicine markets, fostering access to medicine, reducing medicine shortages and addressing major health crises, supporting policy measures for sustainable pricing, promoting efficient regulatory standards, and developing a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value-added medicines industries.
He is also member, and former president, of the European Medicines Verification Organization (EMVO) board for the implementation of serialization against falsified medicines, the vice-chair of the International Generic and Biosimilar medicines Association (IGBA) and a member of the joint industry advisory council of the Health Emergency and Response Authority (HERA).
